Lucid Capital initiated coverage of Ovid Therapeutics (OVID) with a Buy rating and $5.50 price target The firm says Ovid is developing drugs to treat epilepsies and seizure-related neurological disorders. The company’s OV329 could capture a significant market share in drug-resistant epilepsy, reaching over $1B in sales in the U.S., five years after launch, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics transferred with Buy rating at B. Riley
- Ovid Therapeutics management to meet with B. Riley
- Ovid Therapeutics Approves Key Proposals at Annual Meeting
- Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
- Ovid enters agreement with Immedica for sale of future ganaxolone royalties